Autoimmune Disease News and Research

RSS

Autoimmune Disease is a condition in which the body recognizes its own tissues as foreign and directs an immune response against them.

Accentia and Biovest exit Chapter 11 as fully restructured organizations

Accentia Biopharmaceuticals, Inc. announced that, effective today, the Company and its majority-owned subsidiary, Biovest International, Inc., have both successfully completed their reorganizations. Pursuant to their respective Plans of Reorganization approved by the bankruptcy court, Accentia and Biovest have now formally exited Chapter 11 as fully restructured organizations.

18 Nov 2010

LFA encouraged by FDA Advisory Committee vote on BENLYSTA for autoimmune disease lupus

Today the U.S. Food and Drug Administration (FDA) Arthritis Advisory Committee voted overwhelmingly (13 to 2) to recommend BENLYSTA® for approval as a treatment for the autoimmune disease lupus. If FDA approved, BENLYSTA would become the first new treatment for lupus in 52 years. While today's vote is a positive step, the FDA still must make a final decision to approve BENLYSTA in the coming weeks.

17 Nov 2010

LRI pleased with FDA Advisory Committee's approval of Benlysta for lupus

The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations are pleased with the U.S. Food and Drug Administration (FDA) Advisory Committee's vote to recommend approval of Benlysta® for active systemic lupus erythematosus (SLE), offering patients new found hope for the first approved treatment option in more than 50 years.

17 Nov 2010

FDA Arthritis Advisory Committee recommends approval of BENLYSTA for SLE

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 2 to recommend that the FDA approve BENLYSTA (belimumab) for the treatment of autoantibody-positive patients with active systemic lupus erythematosus (SLE).

17 Nov 2010

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. announced today that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. Researchers at The University of Texas (UT) Southwestern Medical Center will conduct the study.

17 Nov 2010

Recommendations for safe and effective testing of artificial pancreas systems in real-life settings

Diabetes experts at a meeting convened by the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) took the next step in advancing efforts toward the development of an artificial pancreas: putting forth clinical recommendations to ensure the safe and effective testing of artificial pancreas technology in real-life situations.

11 Nov 2010

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Incyte Corporation announced the presentation of final six-month clinical data from the dose ranging, placebo-controlled Phase IIa trial of its orally available janus kinase (JAK) inhibitor INCB28050 in patients with active rheumatoid arthritis (RA).

11 Nov 2010

Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment

Resolve Therapeutics, LLC today announced that it has entered into an exclusive license with the University of Washington for certain biologic compounds and technology developed to treat autoimmune diseases including systemic lupus erythematosus (SLE).

11 Nov 2010

Abbott presents results of 2 pivotal HUMIRA studies at American College of Rheumatology meeting

Today, Abbott presents results from a pooled analysis of two pivotal HUMIRA® (adalimumab) studies, which look at patients with early and long-standing moderate to severe rheumatoid arthritis (RA), at the American College of Rheumatology meeting in Atlanta.

10 Nov 2010

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented key preclinical findings of the Company's novel oral anti-interferon, MPI-0485520, at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, in Atlanta, Georgia.

10 Nov 2010

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Idera Pharmaceuticals, Inc. today announced two presentations of preclinical data from its autoimmune and inflammatory disease program at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR) in Atlanta, Georgia. One presentation is entitled "IMO-3100, a Toll-like Receptor (TLR) Antagonist, Suppresses TLR7- and TLR9-mediated Immune Responses in Non-human Primates" (#856).

10 Nov 2010

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

UCB and U.S. based partner Immunomedics Inc. announced that results from the phase IIB study, EMBLEM, showed that certain doses of epratuzumab were associated with a meaningful and statistically significant reduction in disease activity in adult patients with moderate to severe active SLE.

10 Nov 2010

Breast cancer patients more likely to have joint pain from taking AIs: Study

Breast cancer patients are more likely to have joint pain from taking aromatase inhibitors if they have advanced stage cancer, according to a study presented at the American College of Rheumatology's annual meeting, held Nov. 7-11, in Atlanta. The study is one of the first to identify factors that increase the likelihood that a patient will suffer joint pain from AI therapy.

10 Nov 2010

Special Surgery investigators to present future of clinical care at ACR annual meeting

Hospital for Special Surgery physicians who focus on lupus, scleroderma and related conditions are traveling from New York City to Atlanta this week to share their recent findings at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

10 Nov 2010

Phytomedics awarded $244,000 QTDP grant for development of RA drug

Phytomedics, Inc., a transformational healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources, announced today that it has been awarded a grant in the amount of $244,000 under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product PMI-001 for Rheumatoid Arthritis. PMI-001 is presently in Phase 2b/3 development.

9 Nov 2010

Joint complaints attributed to breast cancer drugs not linked with inflammatory arthritis or autoimmune disease

A new study suggests joint complaints attributed to aromatase inhibitors (AI), popular breast cancer drugs, are not associated with inflammatory arthritis or autoimmune disease. Because of that, researchers say women who were primarily concerned about the threat of arthritis should be encouraged to continue taking the medication. The findings of the study will be presented Tuesday, Nov. 9 at the 74th Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia

9 Nov 2010

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.

9 Nov 2010

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited today announced that brentuximab vedotin (SGN-35) will be featured in two oral presentations at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 4-7, 2010 in Orlando, FL.

9 Nov 2010

Thirteen myths about arthritis and rheumatic disease

A diagnosis of arthritis or another rheumatic disease can cause someone to feel anxious and even a little overwhelmed. Being a knowledgeable and empowered patient can help alleviate some of those feelings, and being able to navigate through the many misconceptions about arthritis and rheumatic diseases is vitally important.

8 Nov 2010

Crescendo Bioscience launches multi-biomarker blood test for RA

Crescendo Bioscience announced today the commercial launch of Vectra DA, its first-in-class multi-biomarker blood test designed to aid physicians in managing patients with rheumatoid arthritis (RA). Vectra DA analyzes 12 key serum biomarkers to produce a single objective score that quantifies RA disease activity.

8 Nov 2010

Autoimmune Disease News and Research

Further Reading

Accentia and Biovest exit Chapter 11 as fully restructured organizations

LFA encouraged by FDA Advisory Committee vote on BENLYSTA for autoimmune disease lupus

LRI pleased with FDA Advisory Committee's approval of Benlysta for lupus

FDA Arthritis Advisory Committee recommends approval of BENLYSTA for SLE

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

Recommendations for safe and effective testing of artificial pancreas systems in real-life settings

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment

Abbott presents results of 2 pivotal HUMIRA studies at American College of Rheumatology meeting

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

Breast cancer patients more likely to have joint pain from taking AIs: Study

Special Surgery investigators to present future of clinical care at ACR annual meeting

Phytomedics awarded $244,000 QTDP grant for development of RA drug

Joint complaints attributed to breast cancer drugs not linked with inflammatory arthritis or autoimmune disease

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Thirteen myths about arthritis and rheumatic disease

Crescendo Bioscience launches multi-biomarker blood test for RA

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News